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Objective: The aim of this study was to develop, optimize and characterize carbohydrate coated calcium phosphate nanoparticles of Chelidonium 
majus L. extract along with carried out in vivo study to observe activity in the liver. 
Methods: Surface modified calcium phosphate nanoparticles of Chelidonium majus L. extract were developed and optimized. Extract loading and 
particle size were the two responses, effects on which were analyzed. Characterization studies, in vitro extract release and in vivo distribution 
studies were carried out. Also in vivo histopathological analysis was carried out to observe effects of extract loaded nanoparticles in liver of wistar 
albino rats in paracetamol, rifampicin-isoniazid, cisplatin and carbon tetrachloride-induced hepatotoxicity. 
Results: Pareto chart and surface response curve indicated that sonication time, the concentration of lactose and concentration of extract were 
important factors affecting particle size and extract loading. ANOVA was performed and obtained data pointed out that model was significant for both 
responses. Particle size and zeta potential results indicated the stability of prepared nanoparticles along with extract was loaded (37.22 %) satisfactorily 
on coated cores. Characterization studies indicated no interaction between the components and also extract release demonstrated diffusion-controlled 
mechanism. These extract loaded nanoparticles were largely found in the liver than heart, lungs. Hepatoprotective activity of nanoparticles of the extract 
was confirmed by correlating histopathology results of normal, toxic, silymarin treated, extract-treated and formulation treated groups. 
Conclusion: Lactose coated nanoparticles of calcium phosphate proved to be excellent carriers of plant extract. These nanoparticles efficiently 
targeted liver and generated cellular protective action in hepatic damage.  
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INTRODUCTION 
A nanoparticulate drug delivery system is an exclusive area of drug 
delivery which has significant diversity in its own system. Each has 
its own pertinent attributes and exertions. Most significantly, this 
domain of drug delivery system is expanding day by day with one 
type trying to overcome the limitations of the previous type. The 
principal advantage of nanoparticulate drug delivery is related to the 
vast surface area exposure due to the smaller particle size. 
Aquasome is one of those newly developed drug delivery system in 
this area. It is a self-assembled and three-layered surface-modified 
nanoparticulate system which was invented by Nir Kossovsky in 
1994 [1]. There are three layers in the system with each have its 
own crucial role to the entire system. These are core, coating layer of 
polyhydroxy oligomer and layer of the attached biochemically active 
molecule. Core is generally composed of nanocrystalline tin oxide, 
carbon, calcium phosphate and hydroxyapatite. Calcium phosphate 
and hydroxyapatite are the most preferred cores of choice. 
Bioceramics, mainly calcium phosphate is used in bone grafting, 
tissue engineering because it is the principal component of bone. 
Due to its natural occurrence in the human body, it is biocompatible 
and biodegradable in nature. Surface modification was done by 
coating ceramic core with polyhydroxy oligomer or carbohydrates. 
Carbohydrates provide a natural stabilizing effect to the 
biochemically active molecule as well as the whole drug delivery 
system. It provides an aqueous like environment to preserve the 
stability of the biological molecule. So, the probability of toxicity 
generated by the instability of drug delivery system itself can be 
irradiated. These surface-modified nanoparticles proved to be 
efficient enough for successful delivery of haemoglobin [2, 3], insulin 
[4], antigen [5-7], poorly aqueous soluble drugs [8-10], enzyme [11], 
vaccine [12], human interferon [13].  
Chelidonium majus L. (Family–Papaveraceae), also commonly known 
as greater celandine is a well known medicinal plant indigenous to 
Europe and Asia. A plant rich with isoquinoline alkaloids also contains 
divergent class of components [14] like phenolics, flavonoids, 
flavonoidal glycosides, saponins, sterols, organic acids, amino acids. Its 
empirical application as folk medicine made its way throughout the 
vast topography of Europe and also in China. Principal and noteworthy 
applications of Chelidonium majus L., were involved in treatment of 
skin diseases, eye infections, and liver disorders in traditional herbal 
medicinal system and in homeopathy [15].  
In this study, aquasome based on calcium phosphate was developed, 
surface modified and loaded with Chelidonium majus L. extract 
(henceforth it will be called as extract), as a drug delivery system. 
Formulations were developed by statistical design with variation of 
different essential factors during preparation and optimized 
accordingly. After optimization, selected formulation had undergone 
a characterization study along with in vitro extract release process. 
Also distribution of these extract carriers was observed in liver, 
lungs and heart of wistar albino rats. Prepared aquasomes of extract 
was administered to wistar albino rats to observe protective effects 
and nature of protection in the liver. It can be stated that these 
surface-modified extract carriers of calcium phosphate 
nanoparticles were very much biological or natural due to presence 
of biological components into it.  
MATERIALS AND METHODS 
Materials  
Chelidonium majus L. was purchased as a whole dried herb from 
Associated Traders, Kolkata, India and due to this authentication 
process was done by thin-layer chromatography according to French 
Pharmacopoeia, 2002. Details of the procedure were mentioned in 
our previous research paper [16]. Acetone and disodium hydrogen 
phosphate were purchased from Merck Specialities Private Limited 
(Mumbai, India). Calcium chloride was purchased from Qualigens 
Fine Chemicals (Mumbai, India). Lactose monohydrate was 
purchased from Loba Chemie Private Limited (Mumbai, India). 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 12, Issue 4, 2020 
Banerjee et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 248-257 
249 
Silymarin, carbon tetrachloride, fluorescein isothiocyanate-dextran 
and 0.2 micron membrane filter paper were purchased from Sigma-
Aldrich (Bangalore, India). Formaldehyde was purchased from 
Thermo Fisher Scientific India Private Limited (Mumbai, India). 
Rifampicin and isoniazid were obtained as a gift sample from Lupin 
Limited, India. Paracetamol was obtained also as gift sample from 
Cipla Limited, India). Cisplatin injection was purchased (KEMOPLAT, 
Fresenius Kabi Oncology Limited, India). All other reagents were of 
analytical grade. Protocol of in vivo experiment was approved by the 
Institutional Animal Ethical Committee of Gupta College of 
Technological Sciences, Asansol, West Bengal (protocol no. 
GCTS/IAEC/2016-March/09).  
Preparation of plant extract 
Extract was prepared by using the method described in our previous 
research paper [16]. 
Preparation of aquasomes of extract 
Aquasomes were prepared using the method of Vengala et al., 2013 
[10], with required modifications. A statistical design method was 
utilized using Design-Expert software (Version 12.0.2.0, Trial version 
by Stat-Ease, Inc., Minneapolis, USA) to prepare and optimize different 
formulations by varying different parameters which were illustrated 
in table 1. Here Plackett Burman design was followed with eleven 
factors, including one dummy factor. Factors were sonication time (A), 
the concentration of calcium chloride (B), sonication temperature (C), 
the concentration of lactose (D), amount of acetone (E), amount of core 
(F), amount of drug/extract (G), time of contact during drug/extract 
incubation (H), the temperature of drug/extract incubation (J), RPM of 
stirrer at drug/extract incubation (K) and dummy (L). Total number of 
formulation developed was 12.  
Preparation included three steps 
Core preparation  
Disodium hydrogen phosphate solution was added slowly to calcium 
chloride solution under sonication (Probe Sonicator, Frontline 
Electronics and Machinery Private Limited, Gujarat, India). Formed 
precipitate was separated by centrifugation (Cooling Centrifuge, 
Remi Elektrotechnik Limited, Maharashtra, India) and washed with 
double distilled water. Then it was suspended in double distilled 
water to filter through 0.2 micron membrane filter and filtered 
volume was freeze-dried. In this study, cores were prepared by 
varying concentrations of calcium chloride (mol) and the duration of 
sonication (min) at different temperature ( °C) as depicted in table 1. 
  
Table 1: Formulation optimization–1 
Formulation code A B C D E F G H J K L 
F1 150 0.375 4 0.2 1 500 0.5 6 6 1 -1 
F2 30 0.375 30 0.04 1 500 2.5 6 6 -1 1 
F3 150 0.25 30 0.2 0 500 2.5 24 6 -1 -1 
F4 30 0.375 4 0.2 1 50 2.5 24 30 -1 -1 
F5 30 0.25 30 0.04 1 500 0.5 24 30 1 -1 
F6 30 0.25 4 0.2 0 500 2.5 6 30 1 1 
F7 150 0.25 4 0.04 1 50 2.5 24 6 1 1 
F8 150 0.375 4 0.04 0 500 0.5 24 30 -1 1 
F9 150 0.375 30 0.04 0 50 2.5 6 30 1 -1 
F10 30 0.375 30 0.2 0 50 0.5 24 6 1 1 
F11 150 0.25 30 0.2 1 50 0.5 6 30 -1 1 
F12 30 0.25 4 0.04 0 50 0.5 6 6 -1 -1 
 
Polyhydroxy oligomer coating 
Suitable amount of dried ceramic core was added to the lactose 
solution in double-distilled water and sonicated. It was shaken in a 
shaker incubator bath and acetone was added after that. The 
dispersion was centrifuged and coated cores were collected by 
decanting off the supernatant liquid and washing with double 
distilled water. Coated cores were dried at 70 °C in a hot air oven. In 
this step, carbohydrate concentration (mol), amount of core (mg) 
and amount of acetone (ml) were varied (table 1). 
Extract loading 
Extract was added to aqueous dispersion of coated core. It was 
shaken in a shaker incubator bath for suitable period of time and 
after that the dispersion was centrifuged. Extract loaded aquasomes 
were collected by decanting off the supernatant liquid and air dried. 
Concentration (% W/V) was varied along with stirring speed (RPM), 
incubation period (h) and temperature ( °C) in different 
formulations as depicted in table 1 to determine suitable amount of 
extract loading. Further variations were done by changing 
concentration of extract and time of stirring to obtain optimum and 
suitable extract loading.  
Quantification of extract loading in aquasomes 
During the extract loading process, dispersion was centrifuged after 
shaking for a suitable period of time. After centrifugation 
supernatant liquid was collected and absorbance of this supernatant 
was measured at 272 nm using UV-visible spectroscopy (Thermo 
Spectronic UV1 UV-Visible Spectrophotometer, USA). Wavelength 
was selected as per the result of previous research work by the same 
author [17]. Percentage extract loading was calculated by comparing 
it with blank. 
Calcium alginate coating 
Calcium alginate coating was done on extract loaded nanoparticles 
for oral administration [11] during in vivo study. Aquasomes were 
dispersed in sodium alginate solution (0.1% w/v) and added 
dropwise to calcium chloride solution (1% w/v). After 20 min of the 
incubation period, particles were filtered, washed and dried at room 
temperature. Amount of nanoparticles entrapped in calcium alginate 
was determined with the help of the amount of remaining portion of 
nanoparticles left in sodium alginate dispersion. 
Particle size and zeta potential determination 
Particle size and zeta potential were measured (Malvern Zetasizer 
Nano ZS, United Kingdom) to assess the size and stability of 
prepared nanoparticles (without alginate coating). Before particle 
size and zeta potential measurement, samples were dispersed in 
double distilled water and sonicated for 5 min. For zeta potential 
measurement, sonicated formulations were taken into zeta dip cell. 
All the measurements were done at 25 °C.  
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra of Chelidonium majus L. extract and aquasomes loaded 
with extract were recorded using FTIR spectrophotometer 
(Shimadzu IR-Prestige 21, Shimadzu Scientific Corporations Inc., 
USA). Solid sample was mixed with KBr in a ratio of 1:100 and 
grounded thoroughly. This mixture was pressed with the use of a 
hydraulic press to form a pellet. This pellet was placed in the sample 
holder. Liquid sample was placed in liquid cell. Spectra were 
recorded in the wavelength region of 400-4000 cm-1
Differential scanning calorimetry (DSC) 
.  
In this study, core, coated core and extract loaded formulations were 
undergone thermal analysis with the help of a differential scanning 
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calorimeter (Model–Q10, TA Instruments, USA). Samples were 
heated from 25 °C-300 °C (10 °C/min).  
X-ray diffraction study (XRD) 
XRD study was performed to analyze the crystalline behavior of 
extract loaded nanoparticles using X-ray diffractometer (SmartLab, 
Rigaku Corporation, Japan) within the range of 0 °C–80 °C. 
In vitro dissolution study  
In vitro dissolution study was carried out to understand extract 
release from formulation over a period of time. Here it was carried 
out by dialysis method [17, 18] in pH 6.8 phosphate buffer. 
Nanoparticles (without alginate coating) containing 100 mg of 
extract was taken in a dialysis bag. This enclosed dialysis bag was 
kept in 200 ml of pH 6.8 phosphate buffer medium and entire 
medium was under motion with the help of magnetic stirring at 37 
°C. At a definite time interval, a specific amount of sample was 
withdrawn with the replacement of a similar amount buffer. Release 
was checked after the first 30 min and then at 1 h interval up to 8 h. 
Then, after 24 h, the sample was withdrawn to observe any extract 
release. Absorbance of each sample was determined in UV 
spectrophotometer at 272 nm. This UV method was validated 
analytically. A detail of method development and validation was 
mentioned in our previous research paper [16]. 
Preparation of fluorescent doped aquasomes of Chelidonium 
majus L. extract 
Fluorescein isothiocyanate-dextran was loaded in calcium 
phosphate cores of aqua some. Fluorescent doped cores were 
prepared by considering the procedure by Roy et al., 2014 [19]. Here 
procedure followed was the same as F7 core preparation. Only 
fluorescein isothiocyanate-dextran (10 mg/ml) was dissolved in a 
disodium hydrogen phosphate solution. Prepared extract loaded 
nanoparticles were entrapped in alginate. 
Distribution of fluorescent doped aquasomes in different 
organs of rats 
This study was carried out to observe aquasomes distribution in 
different organs like the liver, heart and lungs of albino wistar rats. 
Fluorescein isothiocyanate-dextran doped alginate coated 
aquasomes (containing 500 mg/kg body weight of extract) were 
orally fed to wistar albino rats. After 24 h, rats were sacrificed. 
Specimens of liver, lung and heart were collected for histopathology. 
These histopathology slides were observed under a fluorescence 
microscope (Leica DM 1000, Leica Microsystems, Mumbai, India). 
In vivo study 
Healthy wistar albino rats (bodyweight of 150-200 g) of both sexes 
were selected randomly and kept in their respective cages fifteen 
days before beginning the study. Animals were kept in a 12 h light 
and dark environment each day with food and water ad libitum. 
Temperature and relative humidity in the animal keeping area was 
maintained as 22 °C (±3 °C) and 50-60 %.  
Each group consisted of six rats selected randomly. Details of 
administered dose were given in table 2. Total duration of dosing 
was for fifteen days. Normal control group (Gr-N) was orally 
administered with normal saline daily. Paracetamol induced 
hepatotoxic group (Gr-P1) was administered with paracetamol as a 
single dose on 15th d orally. Silymarin treated group (Gr-P2) was 
administered with silymarin daily and paracetamol the same as Gr-
P1. CMF (Gr-P3) and CME (Gr-P4) treated groups were administered 
with CMF, CME, orally daily and paracetamol the same as Gr-P1 to 
each. Rifampicin-isoniazid induced hepatotoxic group (Gr-RI1) was 
administered each rifampicin and isoniazid daily through the oral 
route. Silymarin treated group (Gr-RI2) was administered with 
silymarin daily and rifampicin with isoniazid the same as Gr-RI1. 
CMF (Gr-RI3) and CME (Gr-RI4) treated groups were administered 
with CMF, CME, orally daily and rifampicin with isoniazid same as 
Gr-RI1 to each. Cisplatin-induced hepatotoxic group (Gr-C1) was 
administered with cisplatin intraperitoneal (i. p.) as a single dose on 
15th
Normal control ClN group (Gr-ClN) was administered with normal 
saline orally daily and vehicle without carbon tetrachloride i. p. twice 
in a w. CCl
 d. Silymarin treated group (Gr-C2) was treated with silymarin 
orally daily and cisplatin the same as Gr-C2. CMF (Gr-C3) and CME 
(Gr-C4) treated groups were administered with CMF, CME, orally 
daily and cisplatin the same as Gr-C2 to each. 
4 was administered as a single dose to induce hepatotoxicity 
twice in a w (Gr-Cl1). Silymarin treated group (Gr-Cl2) was 
administered with silymarin orally daily and CCl4 same as Gr-Cl1. CMF 
(Gr-Cl3) and CME (Gr-Cl4) treated groups were administered with 
CMF, CME orally daily and CCl4 
On 16
same as Gr-Cl1 to each.  
th
  
 d rats were sacrificed and liver specimens were collected for 
histopathological analysis from respective groups. 
Table 2: Details of administered dose during in vivo study 
Description of administration Dose 
Alginate coated Chelidonium majus L. extract loaded nanoparticles amount containing 500 mg/kg bodyweight of extract 
Chelidonium majus L. extract  500 mg/kg bodyweight of extract 
Silymarin 200 mg/kg bodyweight 
Paracetamol 2 g/kg bodyweight 
Rifampicin-isoniazid Each 100 mg/kg bodyweight  
Cisplatin 7.5 mg/kg bodyweight 
Carbon tetrachloride 30 % solution in liquid paraffin, 1 ml/kg body weight 
 
RESULTS AND DISCUSSION 
Formulation development and optimization 
Nanoparticles preparation involved three steps. In each step there 
were various critical factors. In core preparation step, sonication 
temperature and duration of sonication were important factors 
which can cause serious effect on particle size, surface activity and 
subsequent carbohydrate adsorption. Whereas in the coating stage, 
amount of core, the concentration of carbohydrate and amount of 
acetone were the most important factors which also can generate 
variable results in particle size and further extract loading. During 
extract adsorption, the principal concern was with amount of extract 
adsorbed. This effect could be influenced by factors like amount of 
extract, stirring speed, the temperature of incubation and duration 
of stirring or incubation. Since aquasome preparation involves the 
association of multiple factors, it is logical to use a statistical design 
to optimize the formulation development process. Using Plackett-
Burman design helped to eradicate unintended factors. By selecting 
high and low range of each variable, it was suitable and efficient to 
stigmatize how a specific response was altered or rather precise to 
say which factors were important in a specific step of a particular 
experiment. Two responses were analyzed in this design. Response 
1 was drug/extract loading and Response 2 was particle size. 
It was found that extract was loaded with satisfactory percentage 
loading in each formulation. All the extract loaded aquasomes 
exhibited good particle size (less than 300 nm) as shown in table 3. 
Zeta potential values indicated the stability of prepared 
formulations. Also all the formulations except F-3, F-9 and F-11 
exhibited good zeta potential values as shown in table 3. Low zeta 
potential values of F-3, F-9 and F-11 might be due to a slight increase 
in agglomeration behaviour of calcium phosphate, which was also in 
supportive with the higher particle size of those formulations. 
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Table 3: Extract loading quantification along with respective particle size and zeta potential data 
Formulation code Extract loading (%)  Particle size (nm) Zeta potential (mV) 
F1 14.32±0.71 165.00±2.29 -21.15±0.11 
F2 08.66±0.28 137.87±1.69 -20.22±0.08 
F3 12.97±0.77 268.95±0.51 -14.17±0.17 
F4 16.85±1.66 135.45±0.70 -22.42±0.10 
F5 27.21±1.13 125.80±2.43 -20.77±0.10 
F6 25.32±0.87 131.10±1.00 -22.60±0.07 
F7 30.97±0.66 114.72±0.75 -23.52±0.10 
F8 17.43±0.95 161.10±0.86 -20.82±0.08 
F9 12.35±0.53 214.37±0.68 -19.55±0.11 
F10 22.10±1.28 162.45±1.31 -20.27±0.04 
F11 28.32±1.52 281.37±0.71 -13.77±0.10 
F12 17.10±0.56 125.80±0.82 -22.07±0.04 
Each data represent the average of three independent experiment±SD  
 
ANOVA was carried out to determine the significance of the fitted 
model. Model was significant both in case of extract loading and 
particle size. Table 4 showed model F value for drug/extract loading 
was 874.77 denoting model was significant for extract loading. Table 
5 showed model F value for particle size was 39.85 implying that the 
model was significant for particle size also. Factors generating p 
values less than 0.0500 were significant model terms while p values 
greater than 0.1000 implied that model terms were not significant. 
Speed of stirrer, time of contact and temperature during extract 
incubation (above t-value limit) were crucial factors during extract 
loading on coated calcium phosphate cores (fig. 1A). Sonication time, 
sonication temperature and concentration of lactose were significant 
model terms (above t-value limit) influencing particle size of extract 
loaded aquasomes (fig. 1B). Surface response image of particle size 
(fig. 2A) showed that particle size was descending with an increase 
in the concentration of calcium chloride while ascending with 
increase in sonication time. Surface response diagram of 
drug/extract loading (fig. 2B) indicated to the fact that low 
concentration of calcium chloride and higher sonication time 
individually increased extract loading. Concentration of lactose was 
an important factor in both cases, causing an increase in particle size 
and extract loading with increase in concentration. It was also found 
to be interesting that decrease in sonication temperature caused a 
decrease in particle size while an increase in extract loading. Also, 
particle size was decreased with increasing speed of stirrer. Final 
equations in terms of coded factors for extract loading and particle 
size were depicted in equation (1) and (2) 
Extract loading =+19.47-4.18B-0.8650C+0.5133D+1.59E-1.81F-
1.61G+1.79H+1.78J+2.58K+2.67L (1) 
Particle size =+168.67+32.25A-5.96B+29.80C+22.06D-8.63E-7.25H+ 
6.20J-16.42K-3.90L (2) 
 
Table 4: ANOVA for the selected factorial model (response 1: extract/drug loading) 
Source Sum of squares Degrees of freedom Mean square F-value p value  
Model 564.52 10 56.45 874.77 0.0263 significant 
B-Calcium chloride 209.84 1 209.84 3251.59 0.0112  
C-sonication temperature 8.98 1 8.98 139.13 0.0538  
D-concentration of lactose 3.16 1 3.16 49.00 0.0903  
E-amt of Acetone 30.27 1 30.27 469.12 0.0294  
F-amt. of core 39.53 1 39.53 612.56 0.0257  
G-amt of drug 31.23 1 31.23 484.00 0.0289  
H-time of contact 38.38 1 38.38 594.69 0.0261  
J-temperature of drug incubation 38.02 1 38.02 589.17 0.0262  
K-rpm of stirrer at drug incubation 79.77 1 79.77 1236.16 0.0181  
L-dummy2 85.33 1 85.33 1322.31 0.0175  
Residual 0.0645 1 0.0645    
Cor Total 564.59 11     
p value<0.0500 significant model terms, p value>0.1000 non-significant model terms 
 
Table 5: ANOVA for the selected factorial model (response 2: particle size) 
Source Sum of squares Degrees of freedom Mean square F-value p-value  
Model 34811.20 9 3867.91 39.85 0.0247 significant 
A-sonication time 12483.33 1 12483.33 128.62 0.0077  
B-Calcium chloride 426.02 1 426.02 4.39 0.1712  
C-sonication temperature 10658.86 1 10658.86 109.82 0.0090  
D-concentration of lactose 5837.08 1 5837.08 60.14 0.0162  
E-amt of Acetone 893.72 1 893.72 9.21 0.0936  
H-time of contact 631.33 1 631.33 6.50 0.1254  
J-temperature of drug incubation 461.28 1 461.28 4.75 0.1611  
K-rpm of stirrer at drug incubation 3237.37 1 3237.37 33.36 0.0287  
L-dummy2 182.21 1 182.21 1.88 0.3042  
Residual 194.11 2 97.05    
Cor Total 35005.31 11     
p value<0.0500 significant model terms, p value>0.1000 non-significant model terms 
Banerjee et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 248-257 
252 
 
Fig. 1: Pareto chart for extract/drug loading (A) and particle size (B) 
 
 
Fig. 2: Surface response diagrams for extract/drug loading (A) and particle size (B) 
 
In fit statistics data (table 6), R2value is the determination of the 
amount of variation around the mean value interpreted by model 
itself. It was observed that the predicted R2value was in 
reasonable agreement with adjusted R2
 
value for both particle 
size and extract loading. In both of the case values were less than 
0.2. Adequate precision is demonstrated to describe signal to 
noise ratio, the value of which greater than 4 is acceptable. It 
was observed in table 6 that for extract loading, adequate 
precision was 92.3310 and for particle size, it was 18.1773. Both 
values indicated a good signal. 
Table 6: Fit statistics for extract loading and particle size 
Extract loading Particle size 
Std. Dev. 0.2540 R² 0.9999 Std. Dev. 9.85 R² 0.9945 
Mean 19.47 Adjusted R² 0.9987 Mean 168.66 Adjusted R² 0.9695 
Coefficient of 
variation 
1.30 Predicted R² 0.9835 Coefficient of 
variation 
5.84 Predicted R² 0.8004 
  Adequate 
Precision 




Particle size and zeta potential values indicated F7 to be the best 
selection. A second-time optimization was done using F7 coated 
core to achieve further satisfactory extract loading (table 7). 
Here the amount of extract and time of stirring were varied. 
Stirring time was varied between 1 to 6h, but best results were 
observed at 2h. 500 mg of F7 coated core and 1000 mg of extract 
along with 2 h of stirring yielded 37.22 % of average extract 
loading. 
 
Table 7: Formulation optimization–2 
Formulation code Amount of F-7 
coated core (mg) 
Amount of extract (mg) Time of stirring (h) Average percentage extract loading 
(%) 
F-A 500 500 2 14.88±0.31 
F-A4 500 500 4 10.11±0.15 
F-B 500 1000 2 37.22±0.08 
F-C 500 1500 2 15.96±0.06 
Results represent the average of three independent experiment±SD 
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FTIR study 
FTIR spectra (fig. 3A) of extract loaded aquasome showed peaks at 
567.07 cm-1, 601.79 cm-1and 1037.70 cm-1, which are for 
phosphate group present in calcium phosphate. FTIR spectra of 
Chelidonium majus L. extract (fig. 3B) showed a peak at 1080.14 
cm-1 due to stretching vibrations C-O group of carbohydrate. In fig. 
3B, peak at 1388.75 cm-1 was due to C-H bending vibration and 
peak at 1589.34 cm-1 was due to vibration of C=O group present in 
aromatic components [20, 21]. These peaks were shifted a little in 
FTIR spectra of aqua some loaded with Chelidonium majus L. (fig. 
3A) where peaks were observed at 1419.61 cm-1 and 1604.77 cm-1
 
. 
FTIR results indicated that Chelidonium majus L. extract was 
successfully loaded onto coated cores and prepared nanoparticles 
were stable without any interactions between core, carbohydrate 
and extract. 
 
Fig. 3: FTIR spectra of extract loaded aquasome (A) and Chelidonium majus L. extract (B) 
 
 
Fig. 4: DSC thermogram of calcium phosphate (A), lactose coated calcium phosphate (B) and extract loaded aquasomes (C) 
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Differential scanning calorimetry (DSC) 
Endothermic peak of calcium phosphate showed peak at 86.78 °C 
(fig. 4A). Lactose coated core and extract loaded nanoparticles 
showed endothermic peaks at 68.50 °C (fig. 4B) and 63.36 °C (fig. 
4C). Shift in peaks observed due to the adsorption of lactose and 
extract. Endothermic peaks indicated heat absorption during 
phase transitions. Also, all the peaks indicated the absence of 
incompatibility between individual components of the 
formulation. 
X-ray diffraction study (XRD) 
XRD graphs of calcium phosphate core, lactose coated core and extract 
loaded nanoparticles showed intensity lies in between 129-2111 cps (fig. 
5A), 76-2307 cps (fig. 5B) and 165-2998 cps (fig. 5C). In XRD graph of 
extract loaded aquasome (fig. 5C), peaks were appeared indicative of 
amorphous nature of the formulation. Also few sharp peaks were 
present due to presence of crystalline calcium phosphate. XRD peaks 




Fig. 5: XRD peaks, A: calcium phosphate, B: lactose coated calcium phosphate, C: extract loaded aquasomes 
 
In vitro dissolution study 
All of the formulations showed initial burst release followed by 
controlled release during in vitro dissolution study. Release 
mechanism of all the formulations during dissolution followed 
Korsmeyer-peppas and Korsmeyer-peppas with lag model. 
Release pattern was shown in fig. 6. Since in vitro release pattern 
followed Korsmeyer-peppas model, it indicated to the fact that 




Fig. 6: CPR vs time curve of F1-F6 (A), F7-F12 (B) and F-A to F-C (C) indicating in vitro extract release pattern 
 
Distribution of fluorescence doped nanoparticles in different 
organs 
Histopathology slides of liver, lung and heart specimens were 
observed under a fluorescent microscope. Microscopic images 
showed the distribution of aquasomes in the heart, liver and lung 
(fig. 7). Presence of large numbers of fluorescent particles was 
observed in histopathology specimen of the liver (fig. 7B). Very 
few fluorescent particles were observed in both heart (fig. 7A) and 
lungs (fig. 7C) specimens. While comparing, heart specimen 
contained a few higher numbers of particles than lungs. From the 
observations, it could be stated that these surface-modified extract 
carriers of calcium phosphate will be an excellent approach for 
liver targeting. 
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Fig. 7: Distribution of extract loaded aquasomes showed in fluorescence microscopic histopathology images of heart (A), liver (B) and 
lung (C) of wistar albino rat. Presence of nanoparticles marked with yellow circle 
 
In vivo study 
Histopathology image of normal group (fig. 8A) showed normal 
cellular and sinusoidal pattern. No necrosis or dilation or congestion 
was noted in this group. Paracetamol induced hepatotoxic group (fig. 
8B) showed cellular necrosis, infiltration of fatty matter and congested 
sinusoids. Silymarin treated group (fig. 8C) showed normal cellular 
structure depicting protection against paracetamol-induced toxic 
effects on hepatocytes. Both CMF (fig. 8D) treated group and CME 
treated group (fig. 8E) showed the appearance of normal hepatocytes. 
Sinusoidal congestion was more evidenced in the extract treated 
group compared to the formulation treated group. It could be 
concluded that CM extract exerted protective action against 
paracetamol-induced liver damage similarly like other plant extracts 
[22, 23]. Paracetamol caused liver cell damage by covalent binding 
with DNA [24]. So here it could be said that CM extract might hinder 
binding property of paracetamol with DNA.  
But surface-modified nanoparticles of CM extract showed much better 
protection due to efficient liver targeting. It was also quite evidenced 
that both silymarin and CM showed a similar way of protection 
mechanism during paracetamol-induced liver injury. 
  
 
Fig. 8: Histopathological images of liver specimens of wistar albino rats, A: normal treatment group (Gr-N), B: paracetamol treated group (Gr-P1), 
C: silymarin+paracetamol treated group (Gr-P2), D: CMF+paracetamol treated group (Gr-P3), E: CME+paracetamol treated group (Gr-P4) 
 
Rifampicin-isoniazid induced hepatotoxic group (fig. 9A) showed the 
presence of degenerative cells, dilated sinusoids, and vacuolization 
denoting toxic hepatocellular reaction. Silymarin treated group 
showed effective signs of hepatoprotection with less degenerative cells 
and vacuolization (fig. 9B). CMF treated group (fig. 9C) showed a 
better sign of protection than extract-treated group (fig. 9D). Silymarin 
action of prevention is via reduction of oxidative stress or, more 
specifically, reduction of free radical production and it was reported to 
be used as a standard hepatoprotective agent to compare the effect of 
other plant extracts in rifampicin and isoniazid induced liver damage 
[25-27]. Here it could be seen that CM acted in a similar manner like 
silymarin to prevent hepatocytes from oxidative damage. 
 
 
Fig. 9: Histopathological images of liver specimens of wistar albino rats, A: rifampicin+isoniazid treated group (Gr-RI1), B: 
silymarin+rifampicin+isoniazid treated group (Gr-RI2), C: CMF+rifampicin+isoniazid treated group (Gr-RI3), D: 
CME+rifampicin+isoniazid treated group (Gr-RI4) 
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Here cisplatin group (fig. 10A) showed the presence of degenerative 
cells, necrosis around central vein along with vacuolization. 
Silymarin treated group (fig. 10B) showed normal hepatocytes, few 
vacuolizations and sinusoidal dilations. Both CM treated groups (fig. 
10C and fig. 10D) showed normal cellular appearance though better 
protection was observed in the formulation treated group. Still 
sinusoids were dilated in some areas of both groups. Prevention of 
toxic damage of cisplatin by silymarin was reported by Abdelmeguid 
et al., 2010 [28]. Prevention mechanism included antioxidant 
activity of silymarin by blocking the production of free radicals in 
oxidative stress. Here in this study, it could be seen by comparing 
histopathological images of silymarin, CMF and CM extract-treated 
group that both CM and silymarin treated group showed similar 
preventive mechanism in the cellular level. So, it could be said that 
CM also generated antioxidant activity or rather say preventive 
action very much similar like silymarin. 
 
 
Fig. 10: Histopathological images of liver specimens of wistar albino rats, A: cisplatin treated group (Gr-C1), B: silymarin+cisplatin treated 
group (Gr-C2), C: CMF+cisplatin treated group (Gr-C3), D: CME+cisplatin treated group (Gr-C4). 
 
Gr-ClN (fig. 11A) showed normal hepatocellular structure, whereas 
CCl4 induced hepatotoxic group (fig. 11B) showed the appearance of 
necrosis, dilation of sinusoids and fatty infiltration. In Silymarin 
treated group (fig. 11C) cells appeared near normal although 
sinusoidal dilation was visible. Both CMF treated group (fig. 11D) 
and CME group (fig. 11E) showed fatty infiltration and necrosis. 
Appearance of fatty droplets during CM treatment in CCl4
 
 induced 
hepatotoxicity was similarly visible in the research work of Mitra et 
al., 1996 [29]. Intensity of sinusoidal congestion was higher in 
extract-treated group than CMF treated group and by comparing two 
of the histopathology images it could be concluded that sinusoids 
were in the recovering stage in the formulation treated group and 
fatty infiltration was higher in extract-treated group than 
formulation treated group. It could be concluded that CM extract 
generated protective action by restoring the cellular regeneration 
process [30, 31]. Extract loaded aquasomes prevented toxic damage 
to hepatocytes to a level higher than only extract treatment but not 
in the way of silymarin did. 
 
Fig. 11: Histopathological images of liver specimens of wistar albino rats, A: normal treatment group (only vehicle, Gr-ClN), B: CCl4 treated 
group (Gr-Cl1), C: silymarin+CCl4 treated group (Gr-Cl2), D: CMF+CCl4 treated group (Gr-Cl3), E: CME+CCl4 
 
treated group (Gr-Cl4) 
CONCLUSION  
In this work, surface modification of calcium phosphate 
nanoparticles with lactose resulted in the successfully loading of 
Chelidonium majus L. extract. Extract adsorption via non-covalent 
interactions was further confirmed by FTIR interpretations. Glassy, 
aqueous like environment provided by carbohydrate, created a 
potential sustaining and preserving effect to the plant extract. 
Extract loading and particle size, both of the responses were proved 
to be significant and termed as good signal during statistical 
optimization. All the formulations exhibited satisfactory extract 
loading and prepared nanoparticles were stable by conforming to 
characterization study, particle size and zeta potential results. Also, 
it was evidenced that aquasomes of Chelidonium majus L. extract 
were likely to end up more in liver than in the heart and lungs. 
Chelidonium majus L. extract loaded nanoparticle showed efficient 
cellular protective action in liver in a similar manner like silymarin. 
It is known that plant extract contain many hydrophobic 
components. Also, these surface-modified nanocrystalline materials 
are best choice for delivering typically water-insoluble components. 
So, it can be deduced that surface retailoring of calcium phosphate 
nanoparticles with polyhydroxy oligomers will make it as a lucrative 
choice for an excellent extract carrier with liver targeting proficiency 
in the future.  
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